Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.

Brent DA, Emslie GJ, Clarke GN, Asarnow J, Spirito A, Ritz L, Vitiello B, Iyengar S, Birmaher B, Ryan ND, Zelazny J, Onorato M, Kennard B, Mayes TL, Debar LL, McCracken JT, Strober M, Suddath R, Leonard H, Porta G, Keller MB.

Am J Psychiatry. 2009 Apr;166(4):418-26. doi: 10.1176/appi.ajp.2008.08070976.

2.

The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step.

Brent DA.

Depress Anxiety. 2009;26(10):871-4. doi: 10.1002/da.20617. No abstract available.

3.

Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.

Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, Vitiello B, Ritz L, Iyengar S, Abebe K, Birmaher B, Ryan N, Kennard B, Hughes C, DeBar L, McCracken J, Strober M, Suddath R, Spirito A, Leonard H, Melhem N, Porta G, Onorato M, Zelazny J.

JAMA. 2008 Feb 27;299(8):901-13. doi: 10.1001/jama.299.8.901.

4.

[Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].

Hjalmarsson L, Corcos M, Jeammet P.

Encephale. 2005 May-Jun;31(3):309-16. French.

PMID:
16142045
5.

Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response.

Asarnow JR, Emslie G, Clarke G, Wagner KD, Spirito A, Vitiello B, Iyengar S, Shamseddeen W, Ritz L, Mccracken J, Strober M, Suddath R, Leonard H, Porta G, Keller M, Brent D.

J Am Acad Child Adolesc Psychiatry. 2009 Mar;48(3):330-9. doi: 10.1097/CHI.0b013e3181977476.

6.

Pharmacokinetically and clinician-determined adherence to an antidepressant regimen and clinical outcome in the TORDIA trial.

Woldu H, Porta G, Goldstein T, Sakolsky D, Perel J, Emslie G, Mayes T, Clarke G, Ryan ND, Birmaher B, Wagner KD, Asarnow JR, Keller MB, Brent D.

J Am Acad Child Adolesc Psychiatry. 2011 May;50(5):490-8. doi: 10.1016/j.jaac.2011.01.018.

7.

Clinical and psychosocial predictors of suicide attempts and nonsuicidal self-injury in the Adolescent Depression Antidepressants and Psychotherapy Trial (ADAPT).

Wilkinson P, Kelvin R, Roberts C, Dubicka B, Goodyer I.

Am J Psychiatry. 2011 May;168(5):495-501. doi: 10.1176/appi.ajp.2010.10050718.

PMID:
21285141
8.

Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data.

Schneeweiss S, Patrick AR, Solomon DH, Mehta J, Dormuth C, Miller M, Lee JC, Wang PS.

Arch Gen Psychiatry. 2010 May;67(5):497-506. doi: 10.1001/archgenpsychiatry.2010.39.

9.

Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study.

Shamseddeen W, Clarke G, Keller MB, Wagner KD, Birmaher B, Emslie GJ, Ryan N, Asarnow JR, Porta G, Brent DA.

J Child Adolesc Psychopharmacol. 2012 Feb;22(1):29-36. doi: 10.1089/cap.2011.0027.

10.

Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts.

Schneeweiss S, Patrick AR, Solomon DH, Dormuth CR, Miller M, Mehta J, Lee JC, Wang PS.

Pediatrics. 2010 May;125(5):876-88. doi: 10.1542/peds.2009-2317.

11.

Teenaged, depressed, and treatment resistant: what predicts self-harm?

Weissman MM.

Am J Psychiatry. 2009 Apr;166(4):385-7. doi: 10.1176/appi.ajp.2009.09020265. No abstract available.

12.

Newer generation antidepressants for depressive disorders in children and adolescents.

Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD004851. doi: 10.1002/14651858.CD004851.pub3. Review.

PMID:
23152227
13.

Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents.

Hetrick S, Merry S, McKenzie J, Sindahl P, Proctor M.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD004851. Review. Update in: Cochrane Database Syst Rev. 2012;11:CD004851.

PMID:
17636776
14.

TORDIA: unique opportunity to explore half-life theory.

Smith E.

Am J Psychiatry. 2009 Aug;166(8):936; author reply 936-7. doi: 10.1176/appi.ajp.2009.09050601. No abstract available.

PMID:
19651756
15.

Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine.

Gibbons RD, Brown CH, Hur K, Davis J, Mann JJ.

Arch Gen Psychiatry. 2012 Jun;69(6):580-7. doi: 10.1001/archgenpsychiatry.2011.2048. Erratum in: Arch Gen Psychiatry.2013 Aug;70(8):881.

16.

Antidepressants and the risk of suicidal behaviors.

Jick H, Kaye JA, Jick SS.

JAMA. 2004 Jul 21;292(3):338-43.

PMID:
15265848
17.
18.

Suicide attempts and nonsuicidal self-injury in the treatment of resistant depression in adolescents: findings from the TORDIA study.

Asarnow JR, Porta G, Spirito A, Emslie G, Clarke G, Wagner KD, Vitiello B, Keller M, Birmaher B, McCracken J, Mayes T, Berk M, Brent DA.

J Am Acad Child Adolesc Psychiatry. 2011 Aug;50(8):772-81. doi: 10.1016/j.jaac.2011.04.003.

19.

Do suicidal thoughts or behaviors recur during a second antidepressant treatment trial?

Perlis RH, Uher R, Perroud N, Fava M.

J Clin Psychiatry. 2012 Nov;73(11):1439-42. doi: 10.4088/JCP.12m07777.

20.

A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.

Goodyer IM, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, Breen S, Ford C, Barrett B, Leech A, Rothwell J, White L, Harrington R.

Health Technol Assess. 2008 May;12(14):iii-iv, ix-60.

Supplemental Content

Support Center